% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Morfouace:301505,
author = {M. Morfouace and F. Bielle and E. Razis and F. Estrade and
A. Rubio and F. Bautista and T. de Rojas and M. Vieito and
S. Meade and M. Sanson and A. C. Marques and M. Preusser and
H. Hatcher and G. P. Balasubramanian$^*$ and E. Pineda and
L. D'Hondt and J. Duerinck and A. Michotte and C. Mawrin and
T. Ribalta and G. Marucci and V. Golfinopoulos and S. M.
Pfister$^*$ and D. T. Jones$^*$ and M. G. McCabe},
title = {{M}olecular analysis of adolescent and young adult high
grade gliomas in the {SPECTA}-{AYA} study: {P}oorly
characterised tumours with frequent germline alterations.},
journal = {European journal of cancer},
volume = {223},
issn = {0959-8049},
address = {Amsterdam [u.a.]},
publisher = {Elsevier},
reportid = {DKFZ-2025-01044},
pages = {115493},
year = {2025},
abstract = {Adolescent and young adult (AYA) high grade gliomas (HGG)
have the worst survival of AYA malignancies yet are poorly
represented in large-scale molecular datasets.50 AYAs aged
12-29 with newly diagnosed or recurrent HGG and other high
risk central nervous system (CNS) tumours were prospectively
recruited to the EORTC SPECTA platform study and underwent
whole exome sequencing, RNA sequencing and methylation
profiling, with central pathological review. Actionable
mutations were reported and patients followed up for
therapies and outcome.From 46 locally diagnosed HGGs and 4
other recurrent CNS tumours, molecular and pathology review
resulted in histological grade re-classification (n = 10),
diagnostic refinement (n = 9) and revised diagnoses (n = 12)
in a substantial proportion. Pathogenic constitutional
alterations were present in 14 $\%$ overall and were largely
limited to cases with IDH-wildtype glioblastoma and
paediatric-type diffuse HGGs. 91 $\%$ of HGGs had
potentially actionable alterations affecting RAS/RAF/MAPK
(60 $\%),$ PI3K/AKT/mTOR (27 $\%)$ and cell cycle genes (11
$\%).$ High tumour mutational burden (> 10 somatic
non-synonymous mutations per Mb of genome targeted) was
present in 12 $\%$ at diagnosis and 18 $\%$ at recurrence,
all in histological grade 4 tumours. Ten patients' treatment
was modified on the basis of molecular profile, of whom 5
remained on treatment at last follow-up.AYA HGGs comprise a
diverse group of entities; accurate, molecularly-defined
diagnosis is critical to direct primary treatment, determine
risk of genetic predisposition and guide
molecularly-directed therapy. Current services fail to
routinely address diagnosis, personalised molecular
profiling or investigation of therapeutic opportunities for
this high risk, poor prognosis group of rare cancer
patients.},
keywords = {AYA (Other) / Actionable alterations (Other) / Adolescent
(Other) / Constitutional mutations (Other) / High grade
glioma (Other) / Young adult (Other)},
cin = {B062 / HD01 / B360},
ddc = {610},
cid = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331 /
I:(DE-He78)B360-20160331},
pnm = {312 - Funktionelle und strukturelle Genomforschung
(POF4-312)},
pid = {G:(DE-HGF)POF4-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40393126},
doi = {10.1016/j.ejca.2025.115493},
url = {https://inrepo02.dkfz.de/record/301505},
}